Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent therapeutic advances in MS!
Quiz|Articles|April 19, 2026 (Updated: April 15, 2026)
NeurologyLive® Brain Games: April 19, 2026
Author(s)Louie Pasculli, Marco Meglio
Listen
0:00 / 0:00
Key Takeaways
- NeurologyLive Brain Games publishes every Sunday morning, offering three concise questions developed by clinicians and domain experts across neurological care and advocacy.
- Topic coverage includes dementia/Alzheimer disease, epilepsy, headache/migraine, movement disorders, multiple sclerosis, neuromuscular and sleep disorders, and cerebrovascular disease.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is pediatric strokes!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of pediatric strokes!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
Which of the following is the most common risk factor for arterial ischemic stroke in children?
Which imaging modality is preferred for the diagnosis of acute pediatric arterial ischemic stroke?
Which of the following clinical presentations is most common in pediatric arterial ischemic stroke?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of MDS!
The phase 1 ASCEND trial is testing a single intrathecal dose of the investigational AAV9 gene therapy INS1201 in young boys with Duchenne muscular dystrophy.
A quick-read roundup of 10 late-breaking abstracts from the 2026 MDS Congress, from phase 3 Parkinson disease readouts to long-term data in Huntington disease and Tourette syndrome, with the key results that matter for practice.
The designation follows phase 2 ClearMEMory data in which the oral NMDA receptor antagonist improved objective cognitive performance over placebo at 12 weeks.
An analysis of the phase 3 GEMZ trial presented at CNS 2026 showed that fenfluramine produced comparable seizure reductions and safety outcomes in children and adults with CDKL5 deficiency disorder.
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
A post hoc analysis of the phase 2/3 NPC002 trial presented at CNS 2026 showed that the benefit of arimoclomol plus miglustat in Niemann-Pick disease type C emerged as early as 3 months after treatment initiation.
The professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis
2
The Road Ahead for Precision Medicine in Multiple Sclerosis
3
Arimoclomol Plus Miglustat Shows Early, Sustained Slowing of Niemann-Pick Disease Type C Progression
4
Dompé Begins Phase 2 Trial Testing Intranasal Nerve Growth Factor for Cerebral Palsy
5